William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
Cabaletta Bio Is Maintained at Equal-Weight by Wells Fargo
Stifel Maintains Cabaletta Bio(CABA.US) With Buy Rating, Cuts Target Price to $13
Wells Fargo Maintains Cabaletta Bio(CABA.US) With Hold Rating, Cuts Target Price to $3
Cabaletta Bio Is Maintained at Buy by UBS
Cabaletta Bio Price Target Cut to $7.00/Share From $10.00 by UBS
Cabaletta Bio Is Maintained at Overweight by Morgan Stanley
Cabaletta Bio Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target
Cabaletta Bio's Strategic Advances in Myositis Treatment Drive Buy Rating
Analysts Conflicted on These Healthcare Names: Boston Scientific (BSX), Cabaletta Bio (CABA) and Eli Lilly & Co (LLY)
William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25
Cabaletta Bio's Promising Clinical Progress and Strong Buy Rating by Douglas Tsao
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target
Cabaletta Bio Analyst Ratings
William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
William Blair Remains a Buy on Cabaletta Bio (CABA)
Wells Fargo Downgrades Cabaletta Bio(CABA.US) to Hold Rating, Cuts Target Price to $6
Evercore Initiates Cabaletta Bio(CABA.US) With Hold Rating, Announces Target Price $6